Dr. Prabhakar Kore Basic Science Research Center, KLE Academy of Higher Education and Research (KLE University), Belagavi 590010, Karnataka, India.
J Ethnopharmacol. 2019 Feb 10;230:117-125. doi: 10.1016/j.jep.2018.10.020. Epub 2018 Oct 24.
Terminalia arjuna Roxb. (Combretaceae) is traditionally used in Ayurveda medicine and holds ethnomedicinal importance for treatment of gastrointestinal disorders. In view of its anti-inflammatory, antidiarrheal and antioxidant potential, it could be beneficial for the treatment of inflammatory bowel disease (IBD), which is associated with interaction between genetic, environmental factors and intestinal microbiome leading to dysregulated immune responses. This study evaluates the effect of hydroalcoholic extract of Terminalia arjuna bark (TAHA) in trinitrobenzenesulfonic acid (TNBS) model of rat colitis which resembles human IBD.
TAHA (500, 250, 125 mg/kg) was administered orally for 28 days in TNBS induced rats. Response to treatment was assessed by comparing observations in diseased and treated groups using disease activity index (DAI); macroscopic/histological damage; determining oxidative stress indicators: myeloperoxidase, malondialdehyde, nitric oxide, catalase, superoxide dismutase, and reduced glutathione; gene expression of pro-inflammatory cytokines such as IL-6, IL-1β, TNF-α and chemokine: MCP-1. Furthermore, the role of TAHA in altering the gut microbiota profile in rat feces and plasma zinc was also studied.
TAHA treatment in colitic rats directed decreased DAI scores, macroscopic and histologic damage. It also reduced myeloperoxidase, malondialdehyde and nitric oxide level. Whereas, prevented depletion of plasma catalase, superoxide dismutase and glutathione level. In addition, TAHA treatment down-regulated the gene expression of pro-inflammatory mediators and displayed altered beneficial effect on fecal microbiota. Furthermore, enhanced plasma zinc level supported the beneficial effect of TAHA in colitic rats. The dose of TAHA that produced most significant beneficial effect was 500 mg/kg.
TAHA administration relieved the disease activity in TNBS induced colitis by reducing expression of pro-inflammatory cytokines and chemokine, decreasing oxidative stress, and improving plasma zinc level and structure of gut microbiota.
诃子（使君子科）在印度阿育吠陀医学中被传统使用，具有治疗胃肠道疾病的民族医学重要性。鉴于其抗炎、抗腹泻和抗氧化潜力，它可能有益于治疗炎症性肠病（IBD），IBD 与遗传、环境因素和肠道微生物组之间的相互作用导致免疫反应失调有关。本研究评估了诃子树皮水醇提取物（TAHA）在三硝基苯磺酸（TNBS）诱导的大鼠结肠炎模型中的作用，该模型类似于人类 IBD。
TAHA（500、250、125mg/kg）经口给药 28 天，用于 TNBS 诱导的大鼠。通过比较患病组和治疗组的疾病活动指数（DAI）、宏观/组织学损伤、测定氧化应激指标：髓过氧化物酶、丙二醛、一氧化氮、过氧化氢酶、超氧化物歧化酶和还原型谷胱甘肽；促炎细胞因子如白细胞介素 6、白细胞介素 1β、肿瘤坏死因子-α和趋化因子：单核细胞趋化蛋白 1 的基因表达，评估治疗反应。此外，还研究了 TAHA 改变大鼠粪便和血浆锌中肠道微生物群谱的作用。
TAHA 治疗结肠炎大鼠可降低 DAI 评分、宏观和组织学损伤。它还降低了髓过氧化物酶、丙二醛和一氧化氮水平。而防止了血浆过氧化氢酶、超氧化物歧化酶和谷胱甘肽水平的耗竭。此外，TAHA 治疗下调了促炎介质的基因表达，并对粪便微生物群产生了有益的改变作用。此外，增强了血浆锌水平支持了 TAHA 在结肠炎大鼠中的有益作用。产生最显著有益效果的 TAHA 剂量为 500mg/kg。
TAHA 给药通过降低促炎细胞因子和趋化因子的表达、减少氧化应激、改善血浆锌水平和肠道微生物群结构，缓解了 TNBS 诱导的结肠炎的疾病活动。
